Lamisil at and Abreva drug interactions - a phase IV clinical study of FDA data
We study 16,807 people who take Lamisil at or Abreva. There is no drug interaction reported.
The phase IV clinical study analyzes what interactions people who take Lamisil at and Abreva have. It is created by eHealthMe based on reports the from the FDA, and is updated regularly.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
No report is found.
What is Lamisil at?
Lamisil at has active ingredients of terbinafine hydrochloride. eHealthMe is studying from 487 Lamisil at users for its effectiveness, alternative drugs and more.
What is Abreva?
Abreva has active ingredients of docosanol. It is often used in herpes labialis (oral herpes simplex). eHealthMe is studying from 16,320 Abreva users for its effectiveness, alternative drugs and more.
Do you take Lamisil at and Abreva?Personalize this study to your gender and age
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Alternative drugs to, pros and cons of the 2 drugs:
How the study uses the data?
The study uses data from the FDA. It is based on terbinafine hydrochloride and docosanol (the active ingredients of Lamisil at and Abreva, respectively), and Lamisil at and Abreva (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Lamisil at and Abreva.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Exforge Hct vs. Felodipine - a second ago
- Tenormin vs. Fosinopril Sodium - a second ago
- Entocort Ec and Cancer - Throat Or Larynx - 2 seconds ago
- Feldene vs. Ketoprofen - 2 seconds ago
- Aleve and Electrocardiogram St-T Change - 2 seconds ago
- Fluoxetine vs. Thorazine - 19 seconds ago
- Miostat and Bss drug interaction - 20 seconds ago
- Fiorinal W/Codeine vs. Nucynta - 22 seconds ago
- Vasotec vs. Guanidine Hydrochloride - 32 seconds ago
- Ketoconazole and Protein - Urine - 33 seconds ago